Evidence & regulatory context
- Mechanism
- No ChEMBL entity (polymer nanoparticle gene delivery vehicle). search_trials 'PLGA nanoparticles erythropoietin' returned 0 records: no human trial delivers EpoR cDNA in PLGA nanoparticles.
- Target
- Not recorded
- Injury models
- Other
- Reported indication
- Not recorded
- First approval
- Not recorded
- Development stage
- Not recorded
- ChEMBL record
- Not recorded
- ChEMBL max phase
- Not recorded
- Synonyms
- Not recorded
- Note
- Not recorded
Clinical trials 0
0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.
No linked human trial in this dataset.
Preclinical evidence 1
1 studies reported at therapy level; 1 evidence entries itemised.
RatOtherSprague-Dawleyn = 4 animals per group in the hyperoxia experimentInhalation of nebulised aerosol (4 to 6 micrometre droplets) delivered through a tracheal cannula over 3 min under ketamine 50 mg/kg and xylazine 5 mg/kg intraperitoneal anaesthesia2 mg nebulised nanoparticles per animal; cDNA loading 10% w…Single administration 7 days before hyperoxic exposure
Model: Hyperoxia, 90% inspired oxygen in an environmental chamber for 3 days
A single nebulised dose of EpoR cDNA nanoparticles raised pulmonary EpoR expression and ERK1/2 and STAT5 phosphorylation for up to 21 days and reduced hyperoxia-induced septal thickening, oedema, caspase-8 activity and oxidative damage to DNA, protein and lipid, with no effect on the hyperoxia-indu…
Extraction: extract · Supplied extraction confidence: 0.85. Machine-extracted fields require source verification.